Development of a vaginal gel containing 9-deoxo-16,16-dimethyl-9-methylene PGE2 for cervical dilatation and pregnancy termination
- 1 August 1988
- journal article
- research article
- Published by Elsevier in Prostaglandins, Leukotrienes & Essential Fatty Acids
- Vol. 33 (2) , 121-127
- https://doi.org/10.1016/0952-3278(88)90151-2
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Cervical dilatation with 16,16-dimethyl-trans-Δ2-PGE1 methyl ester (CERVAGEM®) prior to vacuum aspirationContraception, 1984
- Comparison of different prostaglandin analogues and laminaria for preoperative dilatation of the cervix in late first trimester abortionContraception, 1983
- Pre-Abortion Treatment with a Singel Vaginal Suppository: Containing 9-Deoxo-16,16-Dimethyl-Pmethylene PGE2in Late First and Early Second Trimester PregnanciesActa Obstetricia et Gynecologica Scandinavica, 1983
- Plasma levels of 9-deoxo-16,15-dimethyl-9-methylene-PGE2 in connection with its development as an abortifacientProstaglandins, 1982
- A comparison of two stable prostaglandin E analogues for termination of early pregnancy and for cervical dilatationContraception, 1980
- Mid-trimester abortion by vaginal administration of 9-deoxo-16, 16-dimethyl-9-methylene-PGE2Contraception, 1980
- Synthesis and biological properties of 9-deoxo-16,16-dimethyl-9-methylene-PGE2Prostaglandins, 1979